alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
KCl Ammonia

Enlarge Enlarge

DAP Urea

Enlarge Enlarge

Market Data

Complete Markets Data (PDF 1.1 MB)

Potash S&D Phosphate S&D Prices Crop Commodities Ocean Freight

(Updated December 13, 2013)

Selected Fertilizer Selected FertilizerPrices (monthly averages) Prices (monthly averages)

Selected Raw Material Prices (monthly Selected Raw Material Prices (monthlyaverages) averages)

Source: Fertecon, Green Markets Source: Fertecon, Green Markets

Source: Fertecon Source: Fertecon

KCl (Spot)

US$/MT STD Grade

Ammonia (Spot)

US$/MT

DAP (Spot)

US$/MT

Urea (Spot)

US$/MT

FOB Vancouver

02 03 04 05 06 07 08 09 10 11 12 13

0

100

200

300

400

500

600

700

800

900

1000

FOB NOLA Barge $/ST Tampa/US Gulf Del

FOB Yuzhnyy

02 03 04 05 06 07 08 09 10 11 12 13

0

100

200

300

400

500

600

700

800

900

1000

1100

DAP FOB Central Florida $/ST DAP FOB Tampa

02 03 04 05 06 07 08 09 10 11 12 13

0

200

400

600

800

1000

1200

1400

FOB NOLA Barge $/ST FOB Middle East (prills)

FOB Yuzhnyy (prills)

02 03 04 05 06 07 08 09 10 11 12 13

0

100

200

300

400

500

600

700

800

900

PotashCorp - Prices Page 1 of 2

http://www.potashcorp.com/customers/markets/market_data/prices/ 12/30/2013
Sulfur Natural NaturalGas

Enlarge Enlarge

Last Reviewed: Dec 13, 2013 

Source: Fertecon Source: Fertecon *estimated average price paid by ammonia producers

Sulfur

US$/MT

Natural Gas*

US$/MMBtu

Central Florida Del $USD/LT FOB Vancouver

02 03 04 05 06 07 08 09 10 11 12 13

-100

0

100

200

300

400

500

600

700

800

Russia (contract) Netherlands (contract)

US Gulf (spot)

02 03 04 05 06 07 08 09 10 11 12 13

-2

0

2

4

6

8

10

12

14

16

18

PotashCorp - Prices Page 2 of 2

http://www.potashcorp.com/customers/markets/market_data/prices/ 12/30/2013
EXHIBIT 31.2

CERTIFICATION

SECTION 302 CERTIFICATION OF OUR CHIEF FINANCIAL OFFICER



I, Perry Law, certify that:



1. I have reviewed this annual report on Form 10-KSB of Smart-tek Solutions, Inc.;



2. Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a

material fact necessary to make the statements made, in light of the circumstances under which such

statements were made, not misleading with respect to the period covered by this report;



3.  Based on my knowledge, the financial statements, and other financial information included in this report,

fairly present in all material respects the financial condition, results of operations and cash flows of the

registrant as of, and for, the periods presented in this report;



4.  The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure

controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and

have:



(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and

procedures to be designed under our supervision, to ensure that material information relating to the

registrant, including its consolidated subsidiaries, is made known to us by others within those

entities, particularly during the period in which this report is being prepared;



(b)

Evaluated the effectiveness of the registrant's disclosure control and procedures and presented in

this report our conclusions about the effectiveness of the disclosure controls and procedures, as of

the end of the period covered by this report based on such evaluation; and



(c)

Disclosed in this report any change in the registrant's internal control over financial reporting that

occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case

of an annual report) that has materially affected, or is reasonably likely to materially affect, the

registrant's internal control over financial reporting; and



5.   The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal

control over financial reporting ,to the registrant's auditors and the audit committee of the registrant's board

of directors (or persons performing the equivalent functions):



(a)

All significant deficiencies and material weaknesses in the design or operation of internal control

over financial reporting which are reasonably likely to adversely affect the registrant's ability to

record, process, summarize and report financial information; and



(b)

Any fraud, whether or not material, that involves management or other employees who have a

significant role in the registrant's internal control over financial reporting.



/s/ Perry Law

------------------------------

Perry Law

Chief Financial Officer



November 7, 2007
# C_2014112EN.01004901.xml

| 14.4.2014 | EN | Official Journal of the European Union | C 112/49 |
| --- | --- | --- | --- |

14.4.2014

EN

Official Journal of the European Union

C 112/49

---

Action brought on 27 January 2014 — UAB MELT WATER v OHIM (Form of a bottle)

OHIM (Form of a bottle)

(Case T-70/14)

2014/C 112/63

Language in which the application was lodged: Lithuanian

Parties

Parties

Applicant: Research and Production Company MELT WATER UAB (Klaipėda, Lithuania) (represented by V. Viešūnaitė, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | set aside the decision of the Fifth Board of Appeal of OHIM of 26 November 2013 in Case R 481/2013-5 and order OHIM to register, as a Community trade mark, the mark consisting of the form of a bottle in respect of which the applicant, Research and Production Company MELT WATER UAB, has sought registration (application No 010 751 584); |
| --- | --- |

—

set aside the decision of the Fifth Board of Appeal of OHIM of 26 November 2013 in Case R 481/2013-5 and order OHIM to register, as a Community trade mark, the mark consisting of the form of a bottle in respect of which the applicant, Research and Production Company MELT WATER UAB, has sought registration (application No 010 751 584);

| — | award costs in favour of the applicant, Research and Production Company MELT WATER UAB; |
| --- | --- |

—

award costs in favour of the applicant, Research and Production Company MELT WATER UAB;

| — | order the defendant, OHIM, to produce the file concerning the action relating to that application for registration of a Community trade mark (application No 010 751 584). |
| --- | --- |

—

order the defendant, OHIM, to produce the file concerning the action relating to that application for registration of a Community trade mark (application No 010 751 584).

Pleas in law and main arguments

Pleas in law and main arguments

Applicant for a Community trade mark: the applicant.

Applicant for a Community trade mark

Community trade mark in respect of which registration is sought: a three-dimensional mark consisting of the form of a bottle, for goods in Class 32 — application No 010 751 584 for registration of a Community trade mark.

Community trade mark in respect of which registration is sought:

Decision of the Examiner: application rejected.

Decision of the Examiner

Decision of the Board of Appeal: appeal dismissed.

Decision of the Board of Appeal

Pleas in law: Articles 4 and 7(1)(b) of Council Regulation (EC) No 207/2009, together with the case-law of the European Union Courts.

Pleas in law:

---
132 STAT. 4432 PUBLIC LAW 115–315—DEC. 14, 2018 

LEGISLATIVE HISTORY—H.R. 3946: 

CONGRESSIONAL RECORD, Vol. 164 (2018): 

May 21, considered and passed House. 

Nov. 27, considered and passed Senate, amended. 

Dec. 10, House concurred in Senate amendments. 

Æ 

Public Law 115–315 

115th Congress 

An Act 

To name the Department of Veterans Affairs community-based outpatient clinic 

in Statesboro, Georgia, the Ray Hendrix Department of Veterans Affairs Clinic. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. NAME OF DEPARTMENT OF VETERANS AFFAIRS COMMUNITY-BASED OUTPATIENT CLINIC, STATESBORO, 

GEORGIA. 

The Department of Veterans Affairs community-based outpatient clinic in Statesboro, Georgia, shall after the date of the 

enactment of this Act be known and designated as the ‘‘Ray Hendrix 

Department of Veterans Affairs Clinic’’ or the ‘‘Ray Hendrix VA 

Clinic’’. Any reference to such clinic in any law, regulation, map, 

document, record, or other paper of the United States shall be 

considered to be a reference to the Ray Hendrix Department of 

Veterans Affairs Clinic. 

Approved December 14, 2018. 

Dec. 14, 2018 

[H.R. 3946] 


dkrause on DSKBC28HB2PROD with PUBLAWS
Exhibit 10.2

                                  TERMS SHEET

The Shareholders of Iceberg Drive Inn, Inc. a Utah Corporation, hereinafter
referred to as Shareholders, and Iceberg Acquisition Corporation (a wholly owned
subsidiary of Precise Life Sciences, Ltd.) and Precise Life Sciences. Ltd agrees
to the following terms for the Purchase of all of Iceberg Drive Inn's
outstanding shares by Iceberg Acquisition Corporation and Precise Life Sciences.
Ltd.

The Shareholders shall tender all of their Common Voting Shares of Iceberg Drive
Inn, Inc. to Iceberg Acquisition Corporation for the following consideration:

1.      Additional Cash Due at Audit Completion and Close

One Hundred Thousand Dollars ($100,000) in wired funds with be paid to majority
shareholders when audited Financial Statements are delivered to Precise Life
Sciences, Ltd or its managers, owners or agents.  It is anticipated the
transaction will close at that time.

 2.      Final Cash Payment

One Hundred Twenty Five Thousand Dollars ($125,000) in wired funds will be paid
to majority shareholders at on April 12, 2003.

 3.      Cash

Cash in the sum of One Million Fifty Thousand US Dollars ($1,050,000.00) will be
paid in five equal quarterly payments of Two Hundred Ten Thousand Dollars
($210,000.00).  The first payment will be paid on July 12, 2003 and follow every
Ninety (90) days thereafter until the balance is paid in full.


4.      Common Voting Stock

Five Hundred Thousand (500,000) shares of Precise Life Sciences, Ltd Voting
Common Stock will be tendered to Shareholders at close. It is understood and
agreed that Precise Life Sciences, Ltd will be the entity that will own and
operate Iceberg Drive Inn, Inc.

 5.      Preferred Stock Ten Dollar Face Value Six Percent Dividend

Three Hundred Thousand (300,000) Shares of $10 dollar face value Precise Life
Sciences, Ltd preferred stock will be tendered to Shareholders at close pursuant
to tax-free exchange.  Each share will yield a dividend of Sixty Cents per year
or 6% of the face value.  Dividend payments will be made quarterly.  Said shares
will be convertible into Common Shares of Precise Life Sciences, Ltd at a ratio
of One Preferred share to Five Common Voting Shares. Shareholders may convert
Preferred Shares to Voting Common Shares at their leisure.

Precise Life Sciences, Ltd may repurchase Preferred Shares from Shareholders
with thirty days written notice for the face value of Ten Dollars ($10.00) per
share.  Shareholders have the option to convert Preferred Shares to Common
Shares at the One Preferred Share to Five Common Shares ratio within the thirty-
day period.

Iceberg Acquisition Corporation

/s/: J. Brown                             Date: February 17,2003
---------------
By: Jerry Brown
Chairman of the Board

/s/: A. Smith                             Date: February 17, 2003
------------------
By:Alan Smith CEO

Precise Life Sciences, Ltd
----------------
/s/: R. Waters                            Date:  February17, 2003
By:Robert Waters President

Iceberg Drive Inn, Inc.
------------------------
/s/: F.K. Christensen                    Date:  February 17, 2003
By: F. Kelly Christensen President / CFO
SUPREME COURT OF THE STATE OF NEW YORK

Appellate Division, Fourth Judicial Department

1156 

KA 12-00749 

PRESENT: CENTRA, J.P., PERADOTTO, LINDLEY, SCONIERS, AND MARTOCHE, JJ. 

 

THE PEOPLE OF THE STATE OF NEW YORK, RESPONDENT, 

V MEMORANDUM AND ORDER

CHRISTOPHER T. WALKER, JR., DEFENDANT-APPELLANT. 

 

THOMAS J. EOANNOU, BUFFALO (JEREMY D. SCHWARTZ OF COUNSEL), FOR

DEFENDANT-APPELLANT. 

MICHAEL J. VIOLANTE, DISTRICT ATTORNEY, LOCKPORT (LAURA T. BITTNER OF

COUNSEL), FOR RESPONDENT. 

 

Appeal from a judgment of the Niagara County Court (Sara S.

Sperrazza, J.), rendered May 26, 2010. The judgment convicted

defendant, upon his plea of guilty, of attempted robbery in the first

degree. 

It is hereby ORDERED that the judgment so appealed from is

unanimously affirmed. 

Memorandum: On appeal from a judgment convicting him upon his

plea of guilty of attempted robbery in the first degree (Penal Law §§

110.00, 160.15 [3]), defendant contends that County Court abused its

discretion in denying his recusal motion made at sentencing. Even

assuming, arguendo, that defendant’s contention survives his valid

waiver of the right to appeal (cf. People v Mahipat, 49 AD3d 1243,

1244), we conclude that it is without merit. The court was not

required to recuse itself from sentencing defendant based on the fact

that it had presided over the codefendant’s trial (see People v

Bennett, 238 AD2d 898, 899-900, lv denied 90 NY2d 855, 90 NY2d 890,

cert denied 524 US 918). “Moreover, none of [the c]ourt’s remarks . .

. was indicative of bias against defendant and, therefore, recusal was

not warranted on [that] basis” (People v Casey, 61 AD3d 1011, 1014, lv

denied 12 NY3d 913; see People v Johnson, 294 AD2d 908, 908, lv denied

98 NY2d 677). Finally, defendant’s valid waiver of the right to

appeal encompasses his contention concerning the denial of his request

for youthful offender status (see People v Rush, 94 AD3d 1449, 1449,

lv denied 19 NY3d 967; People v Farewell, 90 AD3d 1502, 1502, lv

denied 18 NY3d 957).

Entered: November 16, 2012 Frances E. Cafarell

Clerk of the Court
IN THE SUPREME COURT OF THE STATE OF MONTANA No. DA 22
- 0644 STATE OF MONTANA,

Plaintiff and Appellee, v. CHRIS LANDON LOBERG,

Defendant and Appellant
.

**ORDER** Upon consideration of Appellant’s motion for extension of time, and good cause appearing, IT IS HEREBY ORDERED that Appellant is granted an extension of time to and including July 31 , 2023 , within which to prepare, file, and serve Appellant’s opening brief on appeal.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

June 22 2023

06/22/2023

Case Number: DA 22-0644
§ 556.470 Nystatin. ( a ) [Reserved]
( b ) *Tolerances.* The tolerances for nystatin are: ( 1 ) *Cattle.* Edible tissues (excluding milk): Zero.
( 2 ) *Chickens and turkeys.* Edible tissues: Zero.
( c ) *Related conditions of use.* See §§ 524.1600b and 558.430 of this chapter.
**Exhibit31.1**

**CERTIFICATION**

I, Robin Raina, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Ebix, Inc.;

2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respectsthe financial condition, results of operations and cash flows of the registrantas of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, toensure that material information relating to the registrant, including itsconsolidated subsidiaries, is made known to us by others within those entities,particularly during the period in which this report is being prepared;

(b) Evaluated the effectiveness of the registrant’s disclosure controlsand procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this report based on such evaluation; and

(c) Disclosed in this report any change in the registrant’s internalcontrol over financial reporting that occurred during the registrant’s mostrecent fiscal quarter (the registrant’s fourth fiscal quarter in the case of anannual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financial reporting;and

5. The registrant’s other certifying officer and I have disclosed,based on our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee of theregistrant’s board of directors (or persons performing the equivalentfunctions):

(a) All significant deficiencies and material weaknesses in the designor operation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant’s ability to record, process,summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management orother employees who have a significant role in the registrant’s internalcontrol over financial reporting.

 
| Date:  May 21, 2007 | /s/ Robin Raina          |   |
|-------------------------------|--------------------------|--------|
|                          | Robin Raina              |   |
|                          | Chief Executive  Officer |   |

 

 

----
# C_2014129EN.01001301.xml

| 28.4.2014 | EN | Official Journal of the European Union | C 129/13 |
| --- | --- | --- | --- |

28.4.2014

EN

Official Journal of the European Union

C 129/13

---

Request for a preliminary ruling from the Tribunal du Travail de Nivelles (Belgium) lodged on 10 February 2014 — Charlotte Rosselle v Institut national d’assurance maladie-invalidité (INAMI), Union nationale des mutualités libres (UNM Libres)

(Case C-65/14)

(2014/C 129/16)

Language of the case: French

Referring court

Tribunal du Travail de Nivelles

Parties to the main proceedings

Applicant: Charlotte Rosselle

Defendants: Institut national d’assurance maladie-invalidité (INAMI), Union nationale des mutualités libres (UNM Libres)

Intervener: Institut pour l'Egalité des Femmes et des Hommes (IEFH)

Question referred

Do sections 1 and 2 of title III, chapter III, of the Royal Decree of 3 July 1996 implementing the Law of 14 July 1994 coordinating compulsory medical care and sickness benefit insurance infringe Council Directive 92/85/EEC of 19 October 1992 on the introduction of measures to encourage improvements in the safety and health at work of pregnant workers and workers who have recently given birth or are breastfeeding (1) and Directive 2006/54/EC of the European Parliament and of the Council of 5 July 2006 on the implementation of the principle of equal opportunities and equal treatment of men and women in matters of employment and occupation (recast) (2) in failing to provide for an exemption from the minimum contribution period for a public servant assigned non-active status for personal reasons who is on maternity leave, whereas such an exemption is provided for a public servant who has resigned or has been dismissed?

---

(1)  
  OJ 1992 L 348, p. 1.

(2)  
  OJ 2006 L 204, p. 23.

---
**UN PUBLISHED** 
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

**No. 14**  **- 1252** 

In re: ANTONIO J. WHITEHEAD, a/k/a T.O. , Petitioner

.

On Petition for Writ of Mandamus

. (No. 3:09

- cr - 00099

- 4; 3:13

- cv - 21626)

Submitted : September 25, 2014 Decided: September 29, 2014

Before WILKINSON and AGEE , Circuit Judges, and DAVIS, Senior Circuit Judge.

Petition denied by un published per curiam opinion

.
Antonio J. Whitehead, Petitioner Pro Se.

Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM: Antonio J. Whitehead petitions for a writ of mandamus, alleging that the district court has unduly delayed in ruling on his 28 U.S.C. § 2255 (2012) motion . He seeks an order from this court directing the di strict court to act. We find the present record does not reveal undue delay in the district court. Accordingly, we grant leave to proceed in forma pauperis and deny the mandamus petition. We dispense with oral argument because the facts and legal conten tions are adequately presented in the materials before th is court and argument would n ot aid the decisional process.

PETITION DENIED
Ernst  &  Young



                         CONSENT OF INDEPENDENT AUDITORS


We  consent  to the incorporation by reference in the Registration Statements on
Form  S-8  (No.  333-81357)  pertaining  to  the Amended and Restated 1993 Stock
Option Plan of PixTech, Inc. and on Form S-3 (No. 333-70927) of our report dated
March 6, 2001, with respect to the consolidated financial statements of PixTech,
Inc.  included  in the Annual Report (Form 10-K) for the year ended December 31,
2000.



                               Ernst & Young AUDIT


                                                           /Ernst & Young AUDIT/
                                         represented by :  Christine Blanc-Patin


Marseilles,  France
March  6,  2001


<PAGE>
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                       2,750,972
<SECURITIES>                                         0
<RECEIVABLES>                                2,043,581
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                      90,024,509
<DEPRECIATION>                              33,113,526
<TOTAL-ASSETS>                             156,586,254
<CURRENT-LIABILITIES>                       11,475,977
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                (29,979,723)
<TOTAL-LIABILITY-AND-EQUITY>               156,586,254
<SALES>                                              0
<TOTAL-REVENUES>                            56,002,667
<CGS>                                                0
<TOTAL-COSTS>                               51,346,906
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                          17,625,998
<INCOME-PRETAX>                            (7,758,291)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (7,758,291)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1400 Hydroxyproline test system. ( a ) *Identification.* A hydroxyproline test system is a device intended to measure the amino acid hydroxyproline in urine. Hydroxyproline measurements are used in the diagnosis and treatment of various collagen (connective tissue) diseases, bone disease such as Paget's disease, and endocrine disorders such as hyperparathyroidism and hyperthyroidism.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2306, Jan. 14, 2000]